An Upgrade on the Surveillance System of SARS-CoV-2: Deployment of New Methods for Genetic Inspection.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
15 Mar 2022
Historique:
received: 23 12 2021
revised: 04 02 2022
accepted: 24 02 2022
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 31 3 2022
Statut: epublish

Résumé

SARS-CoV-2 variants surveillance is a worldwide task that has been approached with techniques such as Next Generation Sequencing (NGS); however, this technology is not widely available in developing countries because of the lack of equipment and limited funding in science. An option is to deploy a RT-qPCR screening test which aids in the analysis of a higher number of samples, in a shorter time and at a lower cost. In this study, variants present in samples positive for SARS-CoV-2 were identified with a RT-qPCR mutation screening kit and were later confirmed by NGS. A sample with an abnormal result was found with the screening test, suggesting the simultaneous presence of two viral populations with different mutations. The DRAGEN Lineage analysis identified the Delta variant, but there was no information about the other three mutations previously detected. When the sequenced data was deeply analyzed, there were reads with differential mutation patterns, that could be identified and classified in terms of relative abundance, whereas only the dominant population was reported by DRAGEN software. Since most of the software developed to analyze SARS-CoV-2 sequences was aimed at obtaining the consensus sequence quickly, the information about viral populations within a sample is scarce. Here, we present a faster and deeper SARS-CoV-2 surveillance method, from RT-qPCR screening to NGS analysis.

Identifiants

pubmed: 35328562
pii: ijms23063143
doi: 10.3390/ijms23063143
pmc: PMC8950365
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

NPJ Vaccines. 2021 Aug 16;6(1):104
pubmed: 34400651
Nat Commun. 2013;4:2636
pubmed: 24149915
Front Public Health. 2021 Nov 30;9:775224
pubmed: 34917580
Elife. 2021 Feb 11;10:
pubmed: 33570490
J Virol. 2011 Jul;85(13):6403-15
pubmed: 21490094
Forensic Sci Int Genet. 2017 Sep;30:93-105
pubmed: 28667863
Brief Bioinform. 2013 Mar;14(2):193-202
pubmed: 22445902
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
J Virol. 2020 Aug 17;94(17):
pubmed: 32571797
Nat Commun. 2020 Nov 26;11(1):6013
pubmed: 33243994
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Sci Rep. 2020 Aug 20;10(1):14031
pubmed: 32820179
Genes (Basel). 2018 Feb 14;9(2):
pubmed: 29443895
PLoS One. 2017 Jan 6;12(1):e0169774
pubmed: 28060945
Vet Clin North Am Small Anim Pract. 2003 Jul;33(4):677-93
pubmed: 12910738
Infect Genet Evol. 2015 Mar;30:1-7
pubmed: 25481279
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Sci Rep. 2021 Oct 15;11(1):20510
pubmed: 34654896
Genome Biol. 2019 Jan 8;20(1):8
pubmed: 30621750
Eur J Med Res. 2021 Jun 8;26(1):51
pubmed: 34103090
PLoS One. 2014 Mar 20;9(3):e90714
pubmed: 24651479
Life (Basel). 2022 Jan 25;12(2):
pubmed: 35207458

Auteurs

José Francisco Muñoz-Valle (JF)

Institute for Research in Biomedical Sciences (IICB), University Center for Health Sciences, University of Guadalajara, Guadalajara 44340, Mexico.

Alberto Antony Venancio-Landeros (AA)

Translational Institute of Genomic Singularity (ITRASIG), Irapuato 36615, Mexico.

Rocío Sánchez-Sánchez (R)

Molecular Design Department, Genes2Life (Grupo T), Irapuato 36615, Mexico.

Karen Reyes-Díaz (K)

Research and Development Department, Genes2Life (Grupo T), Irapuato 36615, Mexico.

Byron Galindo-Ornelas (B)

Research and Development Department, Genes2Life (Grupo T), Irapuato 36615, Mexico.

Wendy Susana Hérnandez-Monjaraz (WS)

Research and Development Department, Genes2Life (Grupo T), Irapuato 36615, Mexico.

Alejandra García-Ríos (A)

Research and Development Department, Genes2Life (Grupo T), Irapuato 36615, Mexico.

Luis Fernando García-Ortega (LF)

Department of Genetic Engineering, Center for Research and Advanced Studies of the National Polytechnic Institute (CINVESTAV), Irapuato 36824, Mexico.

Jorge Hernández-Bello (J)

Institute for Research in Biomedical Sciences (IICB), University Center for Health Sciences, University of Guadalajara, Guadalajara 44340, Mexico.

Marcela Peña-Rodríguez (M)

Laboratory for the Diagnosis of Emerging and Reemerging Diseases (LaDEER), University Center for Health Sciences, University of Guadalajara, Guadalajara 44340, Mexico.

Natali Vega-Magaña (N)

Institute for Research in Biomedical Sciences (IICB), University Center for Health Sciences, University of Guadalajara, Guadalajara 44340, Mexico.
Laboratory for the Diagnosis of Emerging and Reemerging Diseases (LaDEER), University Center for Health Sciences, University of Guadalajara, Guadalajara 44340, Mexico.

Luis Delaye (L)

Department of Genetic Engineering, Center for Research and Advanced Studies of the National Polytechnic Institute (CINVESTAV), Irapuato 36824, Mexico.

Mauricio Díaz-Sánchez (M)

Research and Development Department, Genes2Life (Grupo T), Irapuato 36615, Mexico.

Octavio Patricio García-González (OP)

Translational Institute of Genomic Singularity (ITRASIG), Irapuato 36615, Mexico.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH